Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

Aithal, Guruprasad P., Thomas, James A., Kaye, Philip V., Lawson, Adam, Ryder, Stephen D., Spendlove, Ian, Austin, Andrew S., Freeman, Jan G. +2 more·2008·Gastroenterology

DOI 10.1053/j.gastro.2008.06.047

Cited by (719)

Items 401–500 of 719

Beyond Discrete Diagnoses: Conceptualizing Obesity-associated Metabolic Disorders as a Unified, Dynamic Continuum
Cong Xie, Yulian Yuan, Yunjing Wang, Cong Qi, Wei Wang, Chuan An, Aifeila Aikepaer, Yaofu Zhang, Ge Zhang, Xingzhong Feng et al. · 2025 · Current Obesity Reports
What Are the Current Pharmacological Therapies for Nonalcoholic Fatty Liver Disease?
Deepu David, C. E. Eapen · 2020 · Journal of Clinical and Experimental Hepatology
Selection and Warning of Evidence-Based Antidiabetic Medications for Patients With Chronic Liver Disease
Fu‐Shun Yen, Chih‐Cheng Hsu, James Cheng‐Chung Wei, Ming‐Chih Hou, Chii‐Min Hwu · 2022 · Frontiers in Medicine
NAFLD in Cardiovascular Diseases: A Contributor or Comorbidity?
Bing Y. Chen, W.H. Wilson Tang, Mario Rodriguez, Kathleen E. Corey, Arun Jayant Sanyal, Patrick S. Kamath, Biykem Bozkurt, Hafeez Ul Hassan Virk, Gregg S. Pressman, Jeffrey Victor Lazarus et al. · 2022 · Seminars in Liver Disease
Decreasing the burden of non-alcoholic fatty liver disease: From therapeutic targets to drug discovery opportunities
Ricardo Amorim, Pedro Soares, Daniel Chavarria, Sofia Benfeito, Fernando Cagide, José Teixeira, Paulo Jorge Oliveira, Fernanda Borges · 2024 · European Journal of Medicinal Chemistry
Practical approach to non‐alcoholic fatty liver disease in patients with diabetes
Foong Way David Tai, Wing‐Kin Syn, William Alazawi · 2015 · Diabetic Medicine
Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes
Simona Cernea, Avivit Cahn, Itamar Raz · 2017 · Expert Review of Clinical Pharmacology
Exenatide induces carcinoembryonic antigen‐related cell adhesion molecule 1 expression to prevent hepatic steatosis
Hilda E. Ghadieh, Harrison T. Muturi, Lucia Russo, Christopher C. Marino, Simona S. Ghanem, Saja S. Khuder, Julie C. Hanna, Sukanta Jash, Vishwajeet Puri, Garrett Heinrich et al. · 2017 · Hepatology Communications
Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)
Associazione Italiana per lo Studio del Fegato (AISF), Società Italiana di Diabetologia (SID) and Società Italiana dell’Obesità (SIO) · 2021 · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity
Effects of Pioglitazone Mediated Activation of PPAR-γ on CIDEC and Obesity Related Changes in Mice
Bilal Haider Shamsi, Chaofeng Ma, Saima Naqvi, Yanfeng Xiao · 2014 · PLoS ONE
Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome
Simona Moscatiello, Raffaella Di Luzio, Anna Simona Sasdelli, Giulio Marchesini · 2011 · Expert Opinion on Pharmacotherapy
Targeting nuclear receptors for NASH/MASH: From bench to bedside
R. A. Sinha · 2024 · Liver Research
The influence of pioglitazone on the plasma amino acid profile in patients with nonalcoholic steatohepatitis (NASH)
Eiji Kakazu, Yasuteru Kondo, Masashi Ninomiya, Osamu Sandes Kimura, Futoshi Nagasaki, Yoshiyuki Ueno, Tooru Shimosegawa · 2012 · Hepatology International
Hidden in the Fat: Unpacking the Metabolic Tango Between Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Syndrome
Mariana Boulos, Rabia S. Mousa, Nizar Jeries, Elias Simaan, Klode Alam, Bulus Bulus, Nimer Assy · 2025 · International Journal of Molecular Sciences
Metabolic-dysfunction associated steatotic liver disease and atrial fibrillation: A review of pathogenesis
Bharaj, Inderjeet Singh, Brar, Ajit Singh, Kahlon, Jasraj, Singh, Anmol, Hotwani, Priya, Kumar, Vikash, Sohal, Aalam, Batta, Akash · 2025 · World Journal of Cardiology
Potential Therapeutic Strategies in the Treatment of Metabolic-Associated Fatty Liver Disease
A. Bołdys, Ł. Bułdak, M. Maligłówka, Stanisław Surma, B. Okopień · 2023 · Medicina
Association of glucose-lowering drug target and risk of gastrointestinal cancer: a mendelian randomization study
Yi Yang, Bo Chen, Chongming Zheng, Hao Zeng, Junxi Zhou, Yaqing Chen, Qing Su, Jingxian Wang, Juejin Wang, Yurong Wang et al. · 2024 · Cell & Bioscience
Predictors of Impaired Glucose Regulation in Patients with Non-Alcoholic Fatty Liver Disease
Erifili E. Hatziagelaki, Drosos E. Karageorgopoulos, Athina Chounta, Anastasia Tsiavou, Matthew E. Falagas, George Dimitriadis · 2011 · Experimental Diabetes Research
Non-alcoholic steatohepatitis: An update in pathophysiology, diagnosis and therapy
Hossein Khedmat, Saeed Taheri · 2011 · Hepatitis Monthly
Regional anthropometric measures associated with the severity of liver injury in patients with non‐alcoholic fatty liver disease
Vishnu Subramanian, R. D. Johnston, Philip Kaye, Guruprasad Padur Aithal · 2013 · Alimentary Pharmacology & Therapeutics
The therapy of insulin resistance in other diseases besides type 2 diabetes
Laura Pala, Valeria Barbaro, Ilaria Dicembrini, Carlo Maria Rotella · 2014 · Eating and Weight Disorders - Studies on Anorexia Bulimia and Obesity
The Interlink Between Metabolic-Associated Fatty Liver Disease and Polycystic Ovary Syndrome
Paulina Vidal‐Cevallos, Alejandra Mijangos-Trejo, Misael Uribe, Norberto Carlos Chávez-Tapia · 2023 · Endocrinology and Metabolism Clinics of North America
Non-alcoholic fatty liver disease
Michael Pavlides, Jeremy Cobbold · 2015 · Medicine
When Sugar Reaches the Liver: Phenotypes of Patients with Diabetes and NAFLD
Alba Rojano‐Toimil, Jesús Rivera‐Esteban, Ramiro Manzano-Núñez, Juan Bañares, David M. Selva, Pablo Gabriel-Medina, Roser Ferrer, Juan Manuel Pericàs, Andreea Ciudin · 2022 · Journal of Clinical Medicine
Non-alcoholic steatohepatitis: the therapeutic challenge of a global epidemic.
Marialena Mouzaki, Johane P. Allard · 2012 · Europe PMC (PubMed Central)
Biochemical and histological characterisation of an experimental rodent model of non-alcoholic steatohepatitis – Effects of a peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist and a glucagon-like peptide-1 analogue
Samuel Joseph Daniels, Diana Julie Leeming, Sönke Detlefsen, Maria Fuglsang Bruun, Sara Toftegaard Hjuler, Kim Henriksen, Peter Hein, M.A. Karsdal, Sarah Brockbank, Simon Cruwys · 2019 · Biomedicine & Pharmacotherapy
Insulin resistance in HCV mono-infected and in HIV/HCV co-infected patients: Looking to the future
Calogero Cammà, Salvatore Petta · 2009 · Journal of Hepatology
Current and Emerging Approaches for Hepatic Fibrosis Treatment
Jingguo Li, Biguang Tuo · 2021 · Gastroenterology Research and Practice
Banting memorial lecture 2022: ‘Type 2 diabetes and nonalcoholic fatty liver disease: Partners in crime’
Christopher D. Byrne · 2022 · Diabetic Medicine
CD8+ T cells drive adipose tissue inflammation – A novel clue for NASH pathogenesis?
Yury V. Popov, Detlef Schuppan · 2009 · Journal of Hepatology
Atherosclerosis and Non-Alcoholic Fatty Liver Disease
Şevket Balta · 2022 · Angiology
Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?
Yoshio Sumida, Masashi Yoneda, Hidenori Toyoda, Satoshi Yasuda, Toshifumi Tada, Hideki Hayashi, Yoichi Nishigaki, Yusuke Suzuki, Takafumi Naiki, Asahiro Morishita et al. · 2020 · International Journal of Molecular Sciences
Sodium-glucose cotransporter protein-2 inhibitors and glucagon-like peptide-1 receptor agonists versus thiazolidinediones for non-alcoholic fatty liver disease: A network meta-analysis
Chen Ding, Yaxin Tang, Wenqiang Zhu, Piaopiao Huang, Pingan Lian, Juanli Ran, Xiansheng Huang · 2022 · Acta Diabetologica
Pharmacological therapy of nonalcoholic steatohepatitis
Mariko Hojo, Sumio Watanabe · 2011 · Hepatology Research
Validation of a diet‐induced Macaca fascicularis model of non‐alcoholic steatohepatitis with dietary and pioglitazone interventions
Raul C. Camacho, David Polidori, Tao Chen, Bin Chen, Helen Han Hsu, Bin Gao, Mathieu Marella, Mariusz S. Lubomirski, Traymon Beavers, Javier Cabrera et al. · 2022 · Diabetes Obesity and Metabolism
A proposal from the liver forum for the management of comorbidities in non-alcoholic steatohepatitis therapeutic trials
Raluca Pais, Bertrand Cariou, Mazen Noureddin, Sven Francque, Jörn Markus Schattenberg, Manal F. Abdelmalek, Gadi Lalazar, Sharat Varma, Julie Dietrich, Veronica Miller et al. · 2023 · Journal of Hepatology
TASL Practice Guidance on the Clinical Assessment and Management of Patients with Nonalcoholic Fatty Liver Disease
Yusuf Nadir Yilmaz · 2023 · Hepatology forum/Hepatology forum (Online)
Peroxisome proliferator-activated receptor γ activation ameliorates liver fibrosis—differential action of transcription factor EB and autophagy on hepatocytes and stellate cells
Yunjin J. Yum, Jin Hwa Yoo, Kyuhoon Bang, Ji Eun Jun, In‐Kyung Jeong, Kyu Jeung Ahn, Ho Yeon Chung, You‐Cheol Hwang · 2023 · Hepatology Communications
Role of anti-diabetic medications in the management of MASLD
Scott D. Isaacs, Fiona V Farrelly, Paul Brennan · 2025 · Frontline Gastroenterology
Nonalcoholic fatty liver disease should be considered for treatment allocation in standard management algorithms for type 2 diabetes
Mohammad Shafi Kuchay, Narendra Singh Choudhary, Sunil Kumar Mishra, Anoop Misra · 2020 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
Approach to the Patient With Nonalcoholic Fatty Liver Disease
Renata Belfort‐DeAguiar, Romina Lomonaco, Kenneth J. Cusi · 2022 · The Journal of Clinical Endocrinology & Metabolism
Emerging drugs for non-alcoholic steatohepatitis
Wataru Tomeno, Masato Yoneda, Kento Imajo, Yuji Ogawa, Takaomi Kessoku, Satoru Saito, Yuichiro Eguchi, Atsushi Nakajima · 2013 · Expert Opinion on Emerging Drugs
Expert opinion on current therapies for nonalcoholic fatty liver disease
Claudia Della Corte, Anna Alisi, Raffaele Federico Iorio, Arianna Alterio, Valério Nobili · 2011 · Expert Opinion on Pharmacotherapy
Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease in Adults
Scott S. Malinowski, Jennifer S. Byrd, Allison M. Bell, Marion R. Wofford, Daniel M. Riche · 2013 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
Metabolic syndrome and hepatic resection: improving outcome
Shefali Agrawal, Cherag Daruwala · 2011 · HPB
Effects of Metformin, Pioglitazone, and Silymarin Treatment on Non- Alcoholic Fatty Liver Disease: A Randomized Controlled Pilot Study
Ali Akbar Hajiaghamohammadi, Amir Ziaee, Sonia Oveisi, Homa Masroor · 2012 · Hepatitis Monthly
Non‐Alcoholic Fatty Liver Disease and Nutrition
Stephen Hugh Caldwell, Curtis Kent Argo · 2011
SGLT2 Inhibitors in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) Associated with Sustained Hepatic Benefits, Besides the Cardiometabolic
Mohamad Suki, Ashraf Imam, Johnny Amer, Yael Milgrom, Muhammad Massarwa, Wadi Hazou, Yariv Tiram, Ofer Perzon, Yousra Sharif, Joseph Sackran et al. · 2025 · Pharmaceuticals
Side effect profile of pharmacologic therapies for liver fibrosis in nonalcoholic fatty liver disease: a systematic review and network meta-analysis
Yilin Li, Rong Lei, Honglin Lei, Xiong Qin, Fengjiao Xie, Chengjiao Yao, Peimin Feng · 2022 · European Journal of Gastroenterology & Hepatology
Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review
Kelly Torosian, Esha Lal, Arthur Kavanaugh, Rohit Seth Loomba, Veeral H. Ajmera, Mónica Gumá · 2023 · Seminars in Arthritis and Rheumatism
Comparative Efficacy of Drug Interventions on NAFLD Over 24 Weeks: A Traditional and Network Meta-Analysis of Randomized Controlled Trials
Yifan Wang, Yi He, Weixia Sun, Hekai Yu, Wenxuan Tao, Xiaojin Yu, Dianrong Jia, Yingzhao Liu, Stephen Jacob Pandol, Ling Li · 2024 · Drugs
Practical Approaches to Managing Dyslipidemia in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease
Fernando Bril, Gabriela Alicia Berg, Magalí Barchuk, Juan Patricio Nogueira · 2025 · Journal of Lipid and Atherosclerosis
Efficacy and safety of dapagliflozin compared to pioglitazone in diabetic and non-diabetic patients with non-alcoholic steatohepatitis: A randomized clinical trial
Mona S. Abdel Monem, Abdulmoneim Adel, Maggie Abbassi, Doaa Hamed Abdelaziz, Mohamed Hassany, Maissa El Raziky, Nirmeen Ahmed Sabry · 2025 · Clinics and Research in Hepatology and Gastroenterology
The importance of fatty liver disease in clinical practice
Jeremy Cobbold, Quentin Mark Anstee, Simon David Taylor-Robinson · 2010 · Proceedings of The Nutrition Society
Review article: nuclear receptors and liver disease – current understanding and new therapeutic implications
Diaa Elfaki, Einar Stefan Bjornsson, Keith D. Lindor · 2009 · Alimentary Pharmacology & Therapeutics
Treatment of non-alcoholic fatty liver disease: can we already face the epidemic?
Jef Verbeek, David M Cassiman, Matthias Lannoo, Wim Laleman, Van der Merwe, Chris Verslype, Werner Van Steenbergen, Frederik Nevens · 2013 · PubMed
An overview of alogliptin + pioglitazone for the treatment of type 2 diabetes
Brian Tomlinson, Paul Chan, Christopher Wai Kei Lam · 2021 · Expert Opinion on Pharmacotherapy
Revisiting weight reduction and management in the diabetic patient: Novel therapies provide new strategies
Stanley S. Schwartz, Mary E. Herman · 2015 · Postgraduate Medicine
How to Reduce Cardiovascular Risk in Nonalcoholic Fatty Liver Disease
Abdulrahman Ismaiel, Dan Lucian Dumitrascu · 2020 · American Journal of Therapeutics
Metabolomics-based search for therapeutic agents for non-alcoholic steatohepatitis
Yoshihiko Terashima, Shin Nishiumi, Akihiro Minami, Yuki Kawano, Namiko Hoshi, Takeshi Azuma, Masaru Yoshida · 2014 · Archives of Biochemistry and Biophysics
Novel therapeutic drug identification and gene correlation for fatty liver disease using high-content screening: Proof of concept
Weijia Luo, Ting‐Yu Cheng, Keng-Ieng Wong, Woei-horng Fang, Keng-Mao Liao, Yun-Ting Hsieh, Kang‐Yi Su · 2018 · European Journal of Pharmaceutical Sciences
Ipragliflozin attenuates non-alcoholic steatohepatitis development in an animal model
Asahiro Morishita, Tomoko Tadokoro, Shintaro Fujihara, Hisakazu Iwama, Kyoko Oura, Koji Fujita, Joji Tani, Kei Takuma, M. Nakahara, Tingting Shi et al. · 2022 · PLoS ONE
Review: Current status of therapy in nonalcoholic fatty liver disease
Scott McNear, Stephen A. Harrison · 2009 · Therapeutic Advances in Gastroenterology
Weight Reduction in Diabetes
Stanley S. Schwartz, Anthony N. Fabricatore, Andrea Diamond · 2012 · Advances in experimental medicine and biology
Extract of a polyherbal formulation ameliorates experimental nonalcoholic steatohepatitis
Mohammed Mukhram Azeemuddin, Mohamed Rafiq, Suryakanth Dattatraya Anturlikar, L.M. Sharath Kumar, Pralhad Sadashiv Patki, Uddagiri Venkanna Babu, Shyam Ramakrishnan · 2015 · Journal of Traditional and Complementary Medicine
Management and diagnosis of fatty liver disease
Amanda Schneier, Caitlin Citti, Douglas T. Dieterich · 2015 · Expert Review of Gastroenterology & Hepatology
Hepatic Fibrosis and Cirrhosis
Don C. Rockey, Scott L. Friedman · 2012 · Elsevier eBooks
Pioglitazone: More than just an insulin sensitizer # †
Mark J. Czaja · 2009 · Hepatology
Vitamin E for nonalcoholic steatohepatitis
Jean‐François Dufour, Kris V. Kowdley, Geoffrey William McCaughan, Christian Trautwein · 2010 · Hepatology
Therapeutic Potential of Peroxisome Proliferator-Activated Receptor Modulation in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis
Leonie Gellrich, Daniel Merk · 2017 · Nuclear Receptor Research
Pharmacological therapy for non‐alcoholic steatohepatitis: How efficient are thiazolidinediones?
Vlad Ratziu, Loredana Pienar · 2011 · Hepatology Research
Pioglitazone for the Treatment of Metabolic-Associated Fatty Liver Disease in People Living With HIV and Prediabetes
Sarunporn Kamolvisit, Supphamat Chirnaksorn, Hataikarn Nimitphong, Somnuek Sungkanuparph M. D · 2021 · Cureus
Different sites of actions make different responses to thiazolidinediones between mouse and rat models of fatty liver
Chihiro Ebihara, Megumi Aizawa‐Abe, Mingming Zhao, Valentino Gumbilai, Ken Ebihara · 2022 · Scientific Reports
Comparison of efficacy of anti-diabetics on non-diabetic NAFLD: A network meta-analysis
Dachuan Jin, Zhongfeng Cui, Shunqin Jin, Tao Zhou, Baoqiang Guo, Peng Gao, Guangming Li · 2023 · Frontiers in Pharmacology
Progress in promising anti-fibrotic therapies
Rosanna Santoro, Alessandra Mangia · 2019 · Expert Review of Gastroenterology & Hepatology
Role of diabetologists in the management of nonalcoholic fatty liver disease: Primary prevention and screening/management of fibrosis and cirrhosis
Mohammad Shafi Kuchay, Anoop Misra · 2022 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
Beyond the BMI Paradox: Unraveling the Cellular and Molecular Determinants of Metabolic Health in Obesity
Kyoichiro Tsuchiya, Takahiro Tsutsumi · 2025 · Biomolecules
Why do some glucose‐lowering agents improve non‐alcoholic fatty liver disease whereas others do not? A narrative review in search of a unifying hypothesis
Gea Ciccarelli, Gianfranco Di Giuseppe, Francesca Cinti, Simona Moffa, Teresa Mezza, Andrea Giaccari · 2023 · Diabetes/Metabolism Research and Reviews
Metabolic alterations in spinal and bulbar muscular atrophy
Francesco Francini‐Pesenti, Nicola Vitturi, Silvia Tresso, Gianni Sorarú · 2020 · Revue Neurologique
Management guideline for Werner syndrome 2020 1. Dyslipidemia and fatty liver associated with Werner syndrome
Kazuhisa Tsukamoto, Minoru Takemoto, Yoshitaka Kubota, Toshibumi Taniguchi, Sei‐ichiro Motegi, Akira Taniguchi, Hironori Nakagami, Yoshiro Maezawa, Masaya Koshizaka, Hisaya Kato et al. · 2020 · Geriatrics and gerontology international/Geriatrics & gerontology international
Diet containing dehulled adlay ameliorates hepatic steatosis, inflammation and insulin resistance in rats with non-alcoholic fatty liver disease
Wan-Ju Yeh, Jung Ko, Wei-Yi Cheng, Hsin‐Yi Yang · 2021 · British Journal Of Nutrition
Broad Spectrum of Hepatocyte Inclusions in Humans, Animals, and Experimental Models
Pavel Strnad, Renwar Nuraldeen, Nurdan Güldiken, Daniel Hartmann, Vineet Mahajan, Helmut Denk, Johannes Haybaeck · 2013 · Comprehensive physiology
Thiazolidinedione Therapy for Nonalcoholic Steatohepatitis: Go, Stop, or Proceed With Caution?
Stephen A. Harrison · 2009 · Hepatology
Insulin resistance and oxidative stress: Two therapeutic targets in non-alcoholic steatohepatitis
Cosmin Sebastian Voican, Gabriel Perlemuter · 2010 · Journal of Hepatology
Non-alcoholic fatty liver disease in type 2 diabetes: Emerging evidence of benefit of peroxisome proliferator-activated receptors agonists and incretin-based therapies
Subhodip Pramanik, Partha Pal, Sayantan Ray · 2024 · World Journal of Methodology
New advances in drug development for metabolic dysfunction-associated diseases and alcohol-associated liver disease
Jinming Zhang, Yixin Li, Yang Liu, Ningning Ma, Shengying Qian, Yingfen Chen, Yajun Duan, Xiaogang Xiang, Yong He · 2024 · Cell & Bioscience
Factors associated with advanced hepatic fibrosis in patients with various internal diseases: A multicenter community‐based survey
Takumi Kawaguchi, Tetsuaki Inokuchi, Tomoki Honma, Satoshi Itano, Eiji Kawasaki, Chizuko Inada, Toshichika Aoki, Naohira Tsumura, Akiteru Araki, Tokunori Mukae et al. · 2018 · Hepatology Research
The effects of the voglibose on non-alcoholic fatty liver disease in mice model
Jaehyun Bae, Ji Young Lee, Eugene Shin, Minyoung Lee, Yong‐ho Lee, Byung‐Wan Lee, Eun Seok Kang, Bong Soo · 2022 · Scientific Reports
Comparative efficacy of diabetes medications on liver enzymes and fat fraction in patients with nonalcoholic fatty liver disease: A network meta-analysis,,
Caiyan Zou, Yan Sun, Jun Liang · 2022 · Clinics and Research in Hepatology and Gastroenterology
Glitazones for human nonalcoholic steatohepatitis
Raluca Pais, I Moraru, Vlad Ratziu · 2011 · Therapeutic Advances in Gastroenterology
Nonalcoholic Fatty Liver Disease
Melissa Palmer · 2014 · Springer eBooks
Can Nonalcoholic Steatohepatitis be Diagnosed Without Liver Biopsy?
Vlad Ratziu, L. del Olmo Martín, Larysa Fedchuk, Thierry Poynard · 2009 · Biomarkers in Medicine
Sodium-glucose cotransporter-2 inhibitors improve liver enzymes in patients with co-existing non-alcoholic fatty liver disease: a systematic review and metanalysis
Waseem Amjad, Adnan Malik, Waqas Qureshi, Brittany Burns Dennis, Mirrah Mumtaz, Rabbia Haider, Shakeel Muhammad Jamal, Faisal Jaura, Aijaz Ahmed · 2022 · Gastroenterology Review
The crosstalk between insulin resistance and nonalcoholic fatty liver disease/metabolic dysfunction-associated fatty liver disease: a culprit or a consequence?
Dae-Jeong Koo, Won‐Young Lee · 2022 · Cardiovascular Prevention and Pharmacotherapy
Current approaches to diagnosing and treating nonalcoholic fatty liver disease
Е. Л. Никонов, Aksenov Va · 2018 · Russian Journal of Preventive Medicine
Nonalcoholic Fatty Liver Disease
Henryk Dancygier · 2009 · Springer eBooks
Non-Alcoholic Fatty Liver Disease
Hui-Hui Tan, J. Chang · 2010 · Proceedings of Singapore Healthcare
Lansoprazole prevents the progression of liver fibrosis in non-alcoholic steatohepatitis model rats
Toshio Nishi, Yuta Yamamoto, Naoko Yamagishi, Mikitaka Iguchi, Hideyuki Tamai, Takao Ito, Yoshihiro Tsuruo, Masao Ichinose, Masayuki Kitano, Takashi Ueyama · 2018 · Journal of Pharmacy and Pharmacology
Rosiglitazone or pioglitazone in type 2 diabetes?
Corinne S de Vries, D. L. Russell-Jones · 2009 · BMJ
Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes
Konstantinos Malandris, Konstantinos Charalampidis, Rohit Seth Loomba, Emmanouil Sinakos · 2026 · Current Diabetes Reports